Traws completes enrollment in Phase 2 COVID-19 study

Traws Pharma completed enrollment in a 90‑patient Phase 2 trial of ratutrelvir versus PAXLOVID and reported early tolerability and symptom‑resolution findings.

Traws Pharma announced it has finished enrolling 90 patients in a Phase 2 study comparing its investigational oral COVID-19 drug ratutrelvir to PAXLOVID. The open-label trial includes a separate arm for patients who are ineligible for PAXLOVID. The company reports early data showing tolerability, shortened time to symptom resolution, and no viral rebound events to date. Traws also updated progress on an influenza candidate and recent corporate filings. Key details: - The study enrolled 90 patients in an open-label Phase 2 trial comparing ratutrelvir to PAXLOVID; the ratutrelvir arm received 600 mg once daily for 10 days and the comparator arm received standard 5-day PAXLOVID dosing. - The company describes ratutrelvir as a ritonavir-free Mpro/3CL protease inhibitor and reports ongoing data analysis with a favorable tolerability profile, shorter time to symptom resolution, and no viral rebound events to date. - The article mentions the company is listed on NASDAQ and reports a year-to-date share increase and a market value reported around $19.34 million. - Traws has filed a U.S. Investigational New Drug application for tivoxavir marboxil and is developing a compressed tablet formulation that company statements say may provide up to 28 days of protection. - The company has secured a human influenza prophylaxis challenge study time slot for June 2026 and reported prior Phase 1 blood levels exceeding three times an effective concentration for up to 22 days with an earlier formulation. - Shareholders approved amendments to the 2021 Incentive Compensation Plan and ChemDiv will continue to provide Chemistry, Manufacturing, and Controls services for ratutrelvir. Summary: The article reports that Traws has completed enrollment and is analyzing Phase 2 data for ratutrelvir, with interim findings described as tolerable and associated with faster symptom resolution. For tivoxavir marboxil, the company has filed an IND and scheduled a human influenza challenge study for June 2026; other regulatory or efficacy milestones are undetermined at this time.